The Priority Review

Tag

MindMaze Therapeutics

1 story

Stories

  1. Policy

    MindMaze Therapeutics secures up to CHF 4 million financing

    MindMaze Therapeutics announced agreements for up to CHF 4 million from long-term strategic investors, with CHF 3 million scheduled for November and December 2026 and an option for an additional CHF 1 million until February 28, 2027. The proceeds will support the wider commercial deployment of its neurotherapeutics platform and the launch of MindMotion Lite for home deployment.